TABLE 9.1

Drug-specific and patient factors to consider when selecting antihyperglycemic treatment in adults with type 2 diabetes

Embedded Image
  • *For agent-specific dosing recommendations, please refer to the manufacturers’ prescribing information. †FDA-approved for CVD benefit. ‡FDA-approved for HF indication. §FDA-approved for CKD indication. GI, gastrointestinal; GLP-1 RA, GLP-1 receptor agonist; NASH, nonalcoholic steatohepatitis; SQ, subcutaneous; T2D, type 2 diabetes.